Small molecule · developed by Vicore Pharma
Buloxibutid (also known as C21 or Compound 21) is a drug studied in idiopathic pulmonary fibrosis and COVID-19.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04880642 | Phase 3 | COVID-19 | Completed | VCRE |
| NCT06588686 | Phase 2 | Idiopathic Pulmonary Fibrosis (IPF) | Active not recruiting | VCRE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Idiopathic Pulmonary Fibrosis (IPF)COVID-19
See VCRE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
VCRE catalysts and pipeline →